Bulletin from Moberg Pharma’s AGM 2019

STOCKHOLM, May 15th, 2019. Moberg Pharma AB’s (“Company”) Annual General Meeting took place on Wednesday, May 15th, 2019 in the Company´s premises in Bromma, Sweden.

Adoption of the income statements and the balance sheets
The Annual General Meeting (the “Meeting”) approved the income statements and the balance sheets for the fiscal year 2018.

The Meeting resolved, in accordance with the proposal of the Board of Directors, that no dividend should be paid for the fiscal year 2018.

The Meeting discharged the Board members and the Chief Executive Officer from liability for the fiscal year 2018.

Board of Directors
In accordance with the proposal of the Nomination Committee, the Meeting resolved that the Board of Directors shall consist of four (4) persons and no deputies.

The Meeting resolved re-election of Mattias Klintemar and Andrew B. Hochman as Board members of the Board of Directors for a period until the next Annual General Meeting. Thomas Eklund has, after three years as Chairman of the Board and four years as Board member, chosen to resign. Geert Cauwenbergh, Sara Brandt and Anna Malm Bernsten have chosen to resign in order to enable a composition of the Board of Directors that is better adapted to the Company's new situation and focus. In accordance with the proposal of the Nomination Committee, the Meeting resolved election of Peter Wolpert as new Board member and executive Chairman of the Board of Directors, and Fredrik Granström as new Board member. 

The Meeting resolved, in accordance with the proposal of the Nomination Committee, that an aggregate fee of SEK 870,000 shall be paid to the Board members, of which SEK 360,000 to the Chairman of the Board of Directors and SEK 170,000 for all other Board members elected by the Annual General Meeting. In order to compensate for the additional work that Peter Wolpert will perform in the Company in the capacity of executive Chairman of the Board, the Meeting resolved, in accordance with the proposal of the Nomination Committee, on a fee of SEK 61,000 per month to Peter Wolpert for the part of the work that lies outside the role of Chairman of the Board. 

Fees to the Auditors, for a period until the end of the next Annual General Meeting, are to be paid as per approved invoice.

Nomination Committee
The Meeting resolved, in accordance with the proposal of the Nomination Committee, that the Company shall have a Nomination Committee consisting of four (4) members. The Nomination Committee shall comprise one representative of each of the three largest shareholders or owner groups in the Company in terms of votes as per March 31, 2019, besides the Chairman of the Board of Directors.

Principles for remuneration
The Meeting resolved to approve the Board of Director’s proposal for principles of remuneration to senior executives in Moberg Pharma.

Transfer of shares to cover costs related to previous incentive programs
The Meeting also resolved to approve the Board of Director’s proposal to transfer shares to cover costs related to incentive programs implemented previous years.

New CEO
Immediately following the General Meeting and in accordance with the proposal dated on April 8th, 2019 (http://www.mobergpharma.com/press-releases/2019-04-08/proposed-management-changes-moberg-pharma), the Board of Directors resolved to elect Anna Ljung as the new Chief Executive Officer of Moberg Pharma AB.

About this information
Moberg Pharma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 5:30 pm (CET) on May 15th, 2019.

For additional information, please contact:
Peter Wolpert, Chairman of the Board, telephone: +1 908 432 22 03 (US), +46 70 735 71 35 (Sweden), e-mail: peter.wolpert@mobergpharma.se
Anna Ljung, CEO, telephone: +46 707 66 60 30, e-mail: anna.ljung@mobergpharma.se

About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis, for which phase 3 data in 800+ patients is expected in late 2019 in North America and the first half of 2020 in Europe. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis. Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).

Tags:

About Us

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The ompany’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, NewSkin®, Dermoplast®, Domeboro®. Kerasal Nail® (Emtrix® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).For further information, please visit: www.mobergpharma.com.

Contacts